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breakthrough during therapy. The resistance patterns were as
follows: S122S/R, I132V, T54A/I132V, V156S/I170A, V36M/T54S/
R155K, V36M/R155K and T54/R155K. Boceprevir-S isomer (SCH
534128) median concentration in patients with breakthrough was
48.3 ng/mL (interquartile range 43–58 ng/mL); in others, it was
signiﬁcantly (p 0.019) higher: 151 ng/mL. Low boceprevir plasma
concentration can lead to virologic resistance; therapeutic drug
monitoring should be used to prevent the onset of viral
breakthrough during triple-regimen therapy with boceprevir.
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The ﬁrst two authors contributed equally to this article, and both
should be considered ﬁrst authorHepatitis C virus (HCV) is the etiologic agent of chronic hep-
atitis C (CHC), which affects 170 million people and is a leadingClinical Microbiology and Infection © 2014 European Society of Ccause of cirrhosis and hepatocellular carcinoma [1]. For de-
cades, the standard of care has been the combination of
pegylated interferon alfa (PEG-IFN) and ribavirin (RBV) [2].
Recently, the nonstructural (NS) 3/4A protease inhibitors
telaprevir and boceprevir (BOC) were approved for the
treatment of HCV genotype 1. Triple therapy with PEG-IFN,
RBV and these direct-acting antiviral agents improved the sus-
tained virologic response rate despite an increased occurrence
of toxicity [3]. The HCV virus population has high genetic
variability, and so before treatment both wild-type and mutated
variants are present. Among these variants, mutations confer-
ring drug resistance to NS3 inhibitors were found; therefore,
during triple therapy, resistance-associated variants can be
selected, leading to virologic breakthrough (BT) [4]. Major
variants associated with BOC resistance include the following:
V36M/A, T54A, V55A, R155K/T [5] and A156S; minor muta-
tions are V158I, V170A [6] and M175L [7]. Whether the
resistance-associated variants present before the start of
therapy should be related to treatment failure is not yet well
understood [8]. To our knowledge, no data are available
regarding the role of BOC concentrations in the occurrence of
resistance.
We presented a prospective cohort including 18 patients
with CHC treated with triple therapy (PEG-IFN, RBV, BOC)
enrolled onto our study from January to February 2013 at the
Unit of Infectious Disease ‘Amedeo di Savoia’ Hospital, Turin,
Italy. Patients were previously treated with standard therapy
without sustained virologic response (null or partial response
and relapse) or were therapy naive with advanced ﬁbrosis or
unfavorable interleukin 28B proﬁle.
The lead-in phase with PEG-IFN-α-2a at a dose of 180 μg per
week or PEG-IFN-α-2b at 1.5 μg/kg per week and RBV at 15
mg/kg per day was administered in the ﬁrst month; then BOC
was added at the standard oral dose of 800 mg three times a
day.
The study was conducted in compliance with the Declaration
of Helsinki and with local review board regulations. BOC-S
isomer (SCH 534128) and RBV plasma concentrations at the
end of dosing interval (Ctrough) were measured weekly with two
chromatographic methods, as previously published and
routinely used in our laboratory, with ultra performance liquid
chromatography–tandem mass spectrometry and high-
performance liquid chromatography–UV, respectively [9,10].
Baseline characteristics of the study population are reported
in the Table 1. Nine patients (50%) experienced a virologic BT
during BOC therapy between 1 and 6 months after the start of
treatment. No patients had resistance conferring mutations for
BOC at baseline. Only ﬁve of 18 patients had the following
mutation proﬁles on the NS3 region: S122G (one patient),Clin Microbiol Infect 2015; 21: 205.e1–205.e3
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
http://dx.doi.org/10.1016/j.cmi.2014.07.009
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Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectV170A/132V (one patient), I32V (two patients) and Q80L (one
patient). However, these polymorphisms are known to confer
resistance to other protease inhibitors and were not previously
associated with resistance to BOC [11].
Only two of these ﬁve patients experienced BT, and the
polymorphisms detected at baseline were not found at the time
of BT. The resistance patterns observed in BT were as follows:
S122S/R (n = 1), I132V (n = 2), T54A/I132V (n = 1), V156S/
I170A (n = 1), V36M/T54S/R155K (n = 2), V36M/R155K (n = 1)
and T54/R155K (n = 1).
Median plasma BOC-S concentration at week 2 of treatment
was 65.5 ng/mL (IQR 48–134 ng/mL). BOC-S median plasma
concentration in patients who experienced a BT was 48.3 ng/mL
(IQR 43.0–58.0 ng/mL), while in patients without BT, it was
signiﬁcantly higher (p 0.019, Fig. 1): 151 ng/mL (IQR
87.7–234 ng/mL).
RBV plasma concentration was not signiﬁcantly different
between the two groups (p 0.136): 2064 ng/mL (IQR
1474–2934 ng/mL) vs. 2740 ng/mL, (IQR 2105–3366 ng/mL).
Using the receiver operating characteristic curve, we iden-
tiﬁed the BOC-S cutoff concentration under which there was a
high risk of developing BT, corresponding to 65 ng/mL, with a
sensitivity of 88.9% and a speciﬁcity of 77.8% (positive predic-
tive value 80%; negative predictive value 87.5%).
The occurrence of viral BT is inﬂuenced by three major
factors: (a) genetic barrier related to employed drugs [12]
(BOC and telaprevir are deﬁned low-genetic-barrier protease
inhibitors); (b) ﬁtness of viral variant population [6]; and (c)
drug exposure, which may be inﬂuenced by inadequate
adherence. The pharmacokinetics of oral administration of
BOC is strongly related to drug absorption: food intake
increased the area under curve of BOC by 65% compared toFIG. 1. Differences in the distribution of BOC-S isomer plasma con-
centrations between patients with or without virologic breakthrough
(P = p value).
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 205.e1–205.e3
CMI Boglione et al. Early Boceprevir-S isomer plasma concentrations 205.e3the fasting state (Zhang et al., personal communication).
Furthermore, some studies did not discriminate BOC isomers
and considered a S/R isomer ratio of 2:1, irrespective of
interpatient variability (Center for Drug Evaluation and
Research, http://www.accessdata.fda.gov/drugsatfda_docs/nda/
2011/202258Orig1s000MedR.pdf). With a half-life of 3.4
hours, a missed dose could lead to a suboptimal BOC-S plasma
concentration (in our population, lower than 65 ng/mL), thus
selecting resistant mutants. Suboptimal adherence is a potential
cause of viral BT, as observed in the antiretroviral therapy;
common adverse effects occurring during BOC therapy are
mainly of gastrointestinal origin such as nausea (42–48%) and
diarrhea (24–25%) [13]. In our patients who experienced BT,
these adverse effects often caused the avoidance of one or
more doses or in a delayed assumption, with consequent
changes in pharmacokinetic proﬁles.
As observed by Kuntzen et al. [14], the baseline frequency of
drug resistance mutations was between 5% and 8.6% in 1a
genotype– infected naive patients, and as a consequence, they
considered a pretreatment screening for drug-resistant variants
to be useful. In clinical trials, the selection of resistant variants
happened in 28% to 47% of patients who had a decrease in HCV
RNA lower than 1 log after the lead-in phase, whereas this
happened in only 4% to 8% if the decrease was higher than 1 log
[15]. The development of resistance-conferring mutations
caused nonresponse and BT [16].
In patients with BT, we did not detect any previously
described BOC-resistant variant before treatment, and we
consequently suppose that the BT appearance was related to
the lower drug exposure early after treatment initiation. In fact,
as expected, the NS3 variants detected at baseline were not
associated with virologic BT.
Interestingly, one patient who experienced virologic BT
carried the I132V at baseline, and this variant was still present at
BT. However, it is not possible to assess whether this mutation
played some role in the onset of BT.
Further studies are needed to clarify the optimal therapeutic
range of BOC; our proposal is to use both therapeutic drug
monitoring and baseline resistance testing to improve triple
therapy with BOC.Transparency declarationThe authors declare that they have no conﬂicts of interest.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InReferences[1] Mohd Hanaﬁah K, Groeger J, Flaxman AD, Wiersma ST. Global epide-
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